Cartesian Therapeutics Secures $150M Financing from K2 HealthVentures
Cartesian Therapeutics announced that it has entered into an agreement with K2 HealthVentures, an alternative investment firm that provides flexible, long-term financing solutions in life sciences, to provide a credit facility of up to $150M including an initial $50M tranche. The proceeds from the initial tranche under the credit facility are expected to allow the Company to accelerate the ongoing investment in the commercial launch preparation activities for Descartes-08 in myasthenia gravis and myositis and to extend cash runway into 2028. The Company also announced progress across its pipeline, including updated timelines for all ongoing trials of Descartes-08, an autologous anti-B cell maturation antigen mRNA chimeric antigen receptor T-cell therapy.
